What EditCo does

EditCo Bio, Inc. is a privately held CRISPR genome engineering company founded in early 2024 as a spin-off from Synthego's gene-editing operations, headquartered at 600 Saginaw Drive, Redwood City, California. The company is led by co-founders Travis Maures (CSO) and Paul Dabrowski and operates with 51-100 employees.

The company's core offering is built around XDel, a proprietary multi-guide sgRNA CRISPR technology that deploys three spatially coordinated modified SpCas9 sgRNAs per exon to induce fragment deletions (21+ bp), reportedly achieving >98% average knockout editing efficiency versus single-guide RNA approaches. This is supported by an automated high-throughput platform scalable to hundreds of parallel edits across more than 1,400 cell lines (immortalized, iPSC, and primary T-cells and fibroblasts), proprietary ICE CRISPR Analysis software for Sanger sequencing verification, and NGS-based genotyping QC on every product. EditCo monetizes across three streams: (1) custom engineered cell products and services (knockout and knock-in pools and clones, including TAG WHAT MATTERS endogenous protein tagging using licensed Promega HiBiT, NanoLuc, and HaloTag technologies), priced via quotation with milestone-based billing; (2) CRISPR reagents and kits (Gene Knockout Kits, Arrayed sgRNA Libraries, Nucleases, Controls, transfection reagents) sold through a self-serve webstore at unit pricing; and (3) bespoke cell line development services on a professional-services basis.

EditCo serves academic and government research institutions, biotechnology companies, pharmaceutical companies, and contract research organizations, with named customers including the National Institutes of Health, ATCC, Arctoris, Evariste, Université de Toulouse researchers, and academic PIs. GTM combines product-led growth (webstore, referral program, promo codes, webinars, ICE free tool) with enterprise field sales for engineered cell services. The company has built an 8+ partner Discovery Ecosystem (ATCC, Arctoris, Promega, Azenta, BrainXell, Curia, PhenoVista, Pluristyx, Evariste) and operates globally with distributor-managed support in certain countries. Intellectual property is anchored by US Patent 11,697,827 covering the Gene Knock-Out Kit, with additional patents pending on the Gene Knock-Out Kit and Arrayed CRISPR gRNA Libraries.

Name

EditCo

Legal name

EditCo Bio, Inc.

Website

https://editco.bio

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

51–100 employees

Short description

EditCo Bio provides CRISPR-engineered cell lines (knockout/knock-in across immortalized, iPSC, and primary cells) and CRISPR reagent kits, powered by its proprietary XDel multi-guide sgRNA technology, selling to academic, biotech, pharma, and government researchers globally.

Ownership category

akta.pro rank

Product category

CRISPR Genome Engineering Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• CRISPR gene editing
• Engineered cell lines
• Knockout cell pools
• CRISPR reagent kits
• Cell line engineering

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Engineered Cell Products and Services: Custom CRISPR gene editing services delivering knockout and knock-in cell pools and clones across immortalized cells, iPS cells, and primary cells (T-cells, fibroblasts). Services are priced via quotation with milestone-based payment structures. Editing efficiency guarantees (e.g., 80% for XDel KO pools) back the products.
2. CRISPR Reagents and Kits: Sale of CRISPR Gene Knockout Kits, Arrayed sgRNA Libraries, Nucleases, Controls, and CRISPR Transfection Reagents. These are packaged products sold directly via the webstore (store.editco.bio), with defined turnaround times (e.g., 5-day shipping for GKO kits).
3. Cell Line Development Services: Custom cell line development services where EditCo collaborates with customers on bespoke editing projects, often involving milestone-based invoicing and feasibility assessments.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

EditCo Bio provides custom CRISPR-engineered cell lines (knockout and knock-in pools and clones across immortalized, iPSC, and primary T-cell and fibroblast cell types) delivered as ready-to-use research products with guaranteed editing efficiency and NGS QC. The company also sells CRISPR reagent kits (Gene Knockout Kits, Arrayed sgRNA Libraries, Nucleases & Controls) directly through its webstore and offers the ICE CRISPR Analysis web tool for Sanger sequencing deconvolution. Its proprietary XDel multi-guide sgRNA method underpins both custom services and self-serve kits.

Product overview

EditCo is a CRISPR gene editing company offering a comprehensive portfolio of engineered cell products and services built around its proprietary XDel multi-guide CRISPR technology. The core offering consists of engineered cell lines (knockout and knock-in) across three cell types: immortalized cells, iPS cells, and primary cells (T cells and fibroblasts), supplemented by CRISPR reagent kits (Gene Knockout Kits, Arrayed sgRNA Libraries, Nucleases & Controls) and the ICE Analysis Tool for CRISPR edit verification. The portfolio also includes endogenous protein tagging services under the TAG WHAT MATTERS brand, incorporating Promega's HiBiT, NanoLuc, and HaloTag technologies. Products are research use only (RUO), with guarantees on editing efficiency and delivery timelines.

Differentiator

Problem solved

Functional benefit

Brands

• XDel: Proprietary multi-guide CRISPR technology that improves knockout efficiency by generating fragment deletions using coordinated sgRNAs targeting a single exon.
• ICE

Products and services

• XDel Knockout Immortalized Cell Lines Ready-to-use CRISPR knockout cell pools and clones in immortalized cell lines, using XDel multi-guide technology for high-efficiency gene knockout with guaranteed editing efficiency. Target delivery of 3–4 weeks for pools and 8–10 weeks for clones.
• XDel Knock-in Immortalized Cell Lines Precision knock-in cell pools and clones for disease modeling and protein studies, enabling precise genomic edits in immortalized cells.
• XDel Knockout iPS Cell Lines CRISPR knockout iPS cell pools and clones with industry-leading editing efficiency in induced pluripotent stem cells while maintaining cell quality and pluripotency.
• XDel Knock-in iPS Cell Lines Advanced CRISPR knock-in edits in iPS cells for neuroscience and regenerative medicine research, using an automated high-throughput process for reproducible iPS cell edits.
• XDel Knockout CD4+ and CD8+ T Cells Edited-to-order primary CD8+ and CD4+ T cell pools for immunology research, providing high editing accuracy and efficiency with consistent, functional T cells for downstream experimental reliability.
• XDel Knockout Fibroblast Cells Made-to-order knockout fibroblast cells for studying autoimmunity, tumor micro-environments, wound healing, and fibrotic diseases using XDel technology for high on-target editing efficiency.
• HiBiT Protein Tag Knock-in Cells Sensitive, scalable, customizable knock-in pools and clones using Promega's HiBiT protein-tagging technology for visualization, quantification, purification, and degradation studies.
• NanoLuc & HaloTag Knock-in Cells Bright, multi-functional luminescent and covalent tagging technologies from Promega for knock-in cell pools and clones, enabling protein visualization and functional studies.
• Gene Knockout Kits Easy-to-use multi-guide CRISPR kits designed for efficient and consistent gene knockouts in any human or mouse protein-coding gene, achieving knockout rates greater than 80% in as few as 5 days with a 50% editing efficiency guarantee under approved protocols.
• Arrayed CRISPR sgRNA Libraries High-throughput arrayed gRNA libraries for robust, reliable CRISPR screening across entire human or mouse protein-coding genomes, with consistently high editing efficiency and delivery starting at 7 days.
• Nucleases and Controls Complete CRISPR experiment reagents including SpCas9 nucleases, gRNA control kits, and CRISPR transfection reagents for streamlined gene editing workflows.
• ICE CRISPR Analysis Tool Free web-based tool for analyzing Sanger sequence files after CRISPR editing, used for inference of CRISPR edits and verification of predicted results; available as ICE v2 and ICE 4.1 Beta.

Quantifiable outcome

• >98% average knockout editing efficiency (vs. single-guide benchmarks)
• +6 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Promega CorporationcoreTechnology or Integration · 22 April 2025EditCo entered a strategic licensing agreement with Promega to incorporate HiBiT, HaloTag, and NanoLuc protein-tagging and bioluminescent detection technologies into its CRISPR knock-in services. This enables functional validation for engineered cell lines, ensuring proper protein expression, stability, and activity for drug discovery and therapeutic research applications. Tom Livelli, Promega Vice President, noted the agreement accelerates scientific innovation by providing researchers with advanced cellular models for precise functional analysis.
• ATCCcoreStrategic or Co-development PartnerStrategic partnership bringing together ATCC's gold-standard authenticated cell lines with EditCo's leading CRISPR tools and gene editing services, enabling researchers to access the highest-quality edited cells with unparalleled speed, precision, reproducibility, and quality.
• ArctoriscoreStrategic or Co-development PartnerPartnership with Arctoris, a tech-enabled drug discovery services company combining wet lab automation and machine learning. The collaboration enables researchers to leverage EditCo's CRISPR editing (XDel Cell Pools) alongside Arctoris' Ulysses automated assay platform for integrated AI-driven drug discovery workflows.
• AzentaminorStrategic or Co-development PartnerAzenta, a leading provider of life sciences solutions, is part of EditCo's Discovery Partnership Ecosystem. Azenta provides genomic services and cold-chain sample management solutions across drug development, clinical research, and advanced cell therapies.
• BrainXellminorStrategic or Co-development PartnerBrainXell provides differentiation services to generate high-purity, iPSC-derived human neurons, astrocytes, and microglia for research use with a focus on drug discovery. Partnered with EditCo through the Discovery Partnership Ecosystem.
• CuriaminorStrategic or Co-development PartnerCuria is a global contract research, development, and manufacturing organization (CDMO) offering products and services across the drug development spectrum. Included in EditCo's Discovery Partnership Ecosystem for complementary service offerings.
• PhenoVistaminorStrategic or Co-development PartnerPhenoVista specializes in modern human cell-based in vitro assay development and analysis using high-content imaging. Partnered with EditCo to enable life scientists to accelerate therapeutic discovery using engineered cells.
• PluristyxminorStrategic or Co-development PartnerPluristyx provides expertise and tools to support development and commercialization of cell therapies, offering unique products, consulting, and contract services including cell banking and expansion. Part of EditCo's Discovery Partnership Ecosystem.
• EvaristecoreStrategic or Co-development PartnerEvariste is an AI-enabled biotech using AI to accelerate drug discovery. In partnership with EditCo and Arctoris, Evariste has used EditCo's XDel Knockout Cell Pools combined with Arctoris' Ulysses platform to validate novel synthetic lethal gene pairs, demonstrating AI-driven target identification validated through CRISPR editing.
• SynthegocoreStrategic or Co-development PartnerEditCo originated within Synthego's pioneering gene-editing landscape and expanded into its own company in early 2024. Synthego continues to reference EditCo products in its customer support materials, and EditCo's journey began within Synthego's operations, making it a foundational strategic relationship.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Synthego: Synthego is the originating parent of EditCo and a leading provider of synthetic guide RNAs and CRISPR reagents, including engineered cell lines and genome editing services. It is the most direct peer given overlapping CRISPR reagent kits, cell line engineering offerings, and shared operational heritage.
• GenScript: GenScript provides CRISPR reagents, gene synthesis, cell line engineering, and protein services to academic and biotech researchers globally. It directly competes in custom engineered cell line services and CRISPR kits with similar turn-around and pricing models.
• Cellecta: Cellecta provides CRISPR screening products, including pooled and arrayed sgRNA libraries, stable cell line generation, and functional genomics services. It overlaps with EditCo's arrayed CRISPR library and custom cell line engineering offerings, serving similar drug discovery customers.
• Twist Bioscience: Twist Bioscience supplies synthetic DNA, sgRNA libraries, and engineered cell lines for research and drug discovery. Its CRISPR tools and custom cell line services compete with EditCo's reagent kits and engineered cell pools/clones in pharma and academic labs.
• VectorBuilder: VectorBuilder offers custom viral vectors, gene editing reagents (CRISPR), and cell line engineering services. It is comparable in providing made-to-order engineered cells, CRISPR reagents, and design-to-delivery workflows for research and preclinical applications.
• Cyagen Biosciences: Cyagen provides custom cell line engineering, CRISPR knockouts/knock-ins, and iPSC services for academic and biotech customers. It competes with EditCo in custom engineered cell pools and clones, particularly in iPSC and disease-model workflows.

Broad incumbents

• Revvity (Horizon Discovery): Revvity's Horizon Discovery business offers engineered cell lines, CRISPR reagents, and functional genomics services for drug discovery research. It is a broad incumbent with extensive pharma relationships and a much wider portfolio spanning reagents, instruments, and software.
• Thermo Fisher Scientific (GeneArt): Thermo Fisher's GeneArt platform provides CRISPR and gene synthesis tools, engineered cell lines, and related services. As a life science tools giant, it competes on scale, breadth, and pharma distribution, with overlapping offerings in synthetic biology and genome engineering.
• Integrated DNA Technologies (IDT, Danaher): IDT, a Danaher subsidiary, is a major supplier of CRISPR oligos, sgRNAs, Alt-R Cas9 nucleases, and reagents for genome editing. It serves overlapping research customers with a broad catalog of tools that compete directly with EditCo's kit business.

Emerging players

• Caribou Biosciences: Caribou Biosciences applies CRISPR-based genome editing to allogeneic cell therapy development and provides research-use CRISPR reagents. While primarily a therapeutics company, its editing platform and cell line expertise make it an emerging adjacent peer with overlap in cell engineering capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EditCo_Bio
• LinkedInlinkedin.com/company/editco-bio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EditCo